Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Seres Therapeutics Inc (MCRB)

8.04   0.26 (3.34%) 01-16 05:44
Open: 7.68 Pre. Close: 7.78
High: 8.04 Low: 7.52
Volume: 783,143 Market Cap: 738M
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.051 - 8.097 8.097 - 8.138
Low: 7.405 - 7.462 7.462 - 7.514
Close: 7.953 - 8.04 8.04 - 8.119

Technical analysis

as of: 2022-01-15 8:48:04 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 10.68     One year: 11.86
Support: Support1: 7.52    Support2: 6.26
Resistance: Resistance1: 9.15    Resistance2: 10.15
Pivot: 8.46
Moving Average: MA(5): 8.17     MA(20): 8.51
MA(100): 7.66     MA(250): 14.50
MACD: MACD(12,26): -0.20     Signal(9): -0.12
Stochastic oscillator: %K(14,3): 11.74     %D(3): 16.30
RSI: RSI(14): 43.69
52-week: High: 29.90  Low: 5.41  Change(%): -66.7
Average Vol(K): 3-Month: 194266  10-Days: 86668

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
MCRB has closed above bottom band by 15.9%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 13 Jan 2022
What You Need To Know About Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Investor Composition - Nasdaq

Tue, 04 Jan 2022
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference - Stockhouse

Mon, 20 Dec 2021
Federated Hermes Kaufmann Fund II Buys GXO Logistics Inc, Seres Therapeutics Inc, Domo Inc, ... - Yahoo Finance

Tue, 26 Oct 2021
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting - Business Wire

Wed, 15 Sep 2021
Why Seres Therapeutics Stock Is Soaring Today - The Motley Fool

Thu, 09 Sep 2021
Seres Therapeutics: Here We Go Again - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

EPS Est This Year -2.510
EPS Est Next Year -2.860
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.625
Sales Per Share 0.327
EBITDA (p.s.) -1.367
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 24.61
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.